EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Primary prevention of cancer-associated venous thrombosis: Rationale and challenges in clinical practice

Ismail Elalamy, Alain Cohen-Solal, Olivier Hanon, Mariana Mirabel, Patrick Mismetti, Jean-Philippe Spano

Current Research in Translational Medicine · 2023

DOI: 10.1016/j.retram.2023.103405 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Research in Translational Medicine, 2023. Verfasst von Ismail Elalamy und 5 weiteren Autor:innen. Beteiligte Einrichtung: Thrombosis Center, Hematology Department (DMU BioGeM), Assistance Publique Hôpitaux de Paris, Sorbonne University of Medicine, Paris, France; Researc…. Hauptthemen laut MEDLINE: Neoplasms, Venous Thrombosis, Primary Prevention. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 54 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer-associated venous thrombosis (CAT) is a common, multifactor event known to complicate the course of cancer and jeopardize a patient's prognosis. The current guidelines regarding the prevention of CAT are sometimes considered insufficiently precise about specific situations, or are poorly applied. The expected benefits of thromboprophylaxis are balanced by the risk of major bleeding induced by anticoagulation, which implies a need to accurately identify ambulatory patients at high risk of thrombosis or hemorrhage. The Khorana score is commonly used for this, but is limited by the non-reproducibility of predicted performance across cancer types, and by the fact that antitumor treatment and cardiovascular risks are not included. The COMPASS-CAT score, which includes those two aspects, was found to be a more accurate predictor of venous thromboembolism in patients with lung cancer, and to better distinguish between patients at low or high risk of thrombosis. The frailty of patients with cancer is also a major issue, and should be taken into account when thromboprophylaxis is considered. According to current guidelines, CAT prophylaxis should be considered for hospitalized patients, those for whom surgery is scheduled, or those with pancreatic cancers. In ambulatory patients, decisions should be made according to patient, cancer and antitumoral treatment characteristics. Low molecular weight heparin is the gold standard of CAT prophylaxis. Despite increased risks of bleeding or drug-drug interactions in cancer patients, direct oral anticoagulants could be alternate options for high-risk ambulatory patients that should be accompanied by a careful global analysis of benefits, harms, and patient preferences.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsVenous ThrombosisPrimary PreventionHumansAnticoagulantsRisk FactorsPractice Guidelines as TopicHemorrhageHeparin, Low-Molecular-WeightRisk Assessment

Stichwörter der Autor:innen

AnticoagulationCancer-associated thrombosisDirect oral anticoagulantsHemorrhageLow molecular weight heparinThromboprophylaxis

Substanzen

AnticoagulantsHeparin, Low-Molecular-Weight

Autor:innen und Institutionen

  • Thrombosis Center, Hematology Department (DMU BioGeM), Assistance Publique Hôpitaux de Paris, Sorbonne University of Medicine, Paris, France; Research Group "Cancer, Haemostasis and Angiogenesis", INSERM U938, Research…
  • Université Paris Cité, INSERM Unité 942 MASCOT, AP-HP, Département de cardiologie et maladies vasculaires, Hôpital Lariboisière, Paris, France.
  • Université Paris Cité, EA4468, AP-HP, hôpitaux Universitaires Paris Centre, Département de Gériatrie, Hôpital Broca, Paris, France.
  • Département de Cardiologie, Institut mutualiste Montsouris, Paris, France.
  • Service de Médecine Vasculaire et Thérapeutique, Centre Hospitalier Universitaire, Saint Etienne, France.
  • Service d'Oncologie médicale, APHP-SU, IUC, Hôpital La Pitié-Salpêtrière, Paris, France.

Zitieren

APA

Elalamy, I., Cohen-Solal, A., Hanon, O., Mirabel, M., Mismetti, P., & Spano, J. P. (2023). Primary prevention of cancer-associated venous thrombosis: Rationale and challenges in clinical practice. Current Research in Translational Medicine. https://doi.org/10.1016/j.retram.2023.103405

Vancouver

Elalamy I, Cohen-Solal A, Hanon O, Mirabel M, Mismetti P, Spano JP. Primary prevention of cancer-associated venous thrombosis: Rationale and challenges in clinical practice. Current Research in Translational Medicine. 2023. doi:10.1016/j.retram.2023.103405

BibTeX
@article{Elalamy2023,
  author = {Elalamy, Ismail and Cohen-Solal, Alain and Hanon, Olivier and Mirabel, Mariana and Mismetti, Patrick and Spano, Jean-Philippe},
  title = {Primary prevention of cancer-associated venous thrombosis: Rationale and challenges in clinical practice},
  journal = {Current Research in Translational Medicine},
  year = {2023},
  doi = {10.1016/j.retram.2023.103405}
}
Kostenlos starten →